Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has been updated to include new information about Chronic Spontaneous Urticaria (CSU) and the involvement of Regeneron Pharmaceuticals as a collaborator, while significant details regarding the study's objectives, duration, and inclusion/exclusion criteria have been removed.SummaryDifference16%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.